Basic Information
| LncRNA/CircRNA Name | TUG1 |
| Synonyms | TUG1, LINC00080, NCRNA00080, TI-227H |
| Region | GRCh38_22:30969245-30979395 |
| Ensemble | ENSG00000253352 |
| Refseq | NR_002323 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Flow cytometry assay, Western blot, Luciferase reporter assay, etc. |
| Sample | RWPE1 and PCa cell lines (DU145, PC-3, LNCaP, 22Rv1). patients in tumor and adjacent normal tissue. |
| Expression Pattern | up-regulated |
| Function Description | In conclusion, our study suggests that lncRNA TUG1 acts as a functional oncogene in PCa development. TUG1 could negatively regulate the expression of miR-26a in PCa cells. The bioinformatics prediction revealed putative miR-26a binding sites within TUG1 transcripts. |
| Pubmed ID | 29967294 |
| Year | 2018 |
| Title | TUG1 promotes prostate cancer progression by acting as a ceRNA of miR-26a. |
External Links
| Links for TUG1 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |